Duke Immune Profiling Core

$68,765P30FY2025CANIH

Duke University, Durham NC

Investigators

Linked publications, trials & patents

Paper 39605338 Paper 39416087 Paper 39320053 Paper 39307527 Paper 39253977 Paper 39238136 Paper 39227594 Paper 39176091 Paper 39146842 Paper 39133651 Paper 39083560 Paper 39075068 Paper 39034366 Paper 39014162 Paper 38976158 Paper 38935899 Paper 38886328 Paper 38886323 Paper 38871555 Paper 38860607 Paper 38826146 Paper 38798534 Paper 38788720 Paper 38771177 Paper 38769385 Paper 38759331 Paper 38742743 Paper 38670986 Paper 38650010 Paper 38623754 Paper 38607917 Paper 38569609 Paper 38519039 Paper 38438700 Paper 38380561 Paper 38359680 Paper 38350748 Paper 38325549 Paper 38272925 Paper 38260522 Paper 38260227 Paper 38242440 Paper 38236581 Paper 38226619 Paper 38106038 Paper 38104870 Paper 38104127 Paper 37985794 Paper 37985571 Paper 37922879 Paper 37909039 Paper 37890720 Paper 37884120 Paper 37857141 Paper 37827871 Paper 37772998 Paper 37760589 Paper 37737622 Paper 37697042 Paper 37696029 Paper 37671594 Paper 37655425 Paper 37619838 Paper 37595184 Paper 37588752 Paper 37575220 Paper 37556556 Paper 37543556 Paper 37523502 Paper 37466869 Paper 37460738 Paper 37442696 Paper 37436874 Paper 37350479 Paper 37315312 Paper 37311534 Paper 37307512 Paper 37306774 Paper 37188803 Paper 37182536 Paper 37173865 Paper 37149546 Paper 37009691 Paper 36966348 Paper 36944149 Trial NCT06529120 Trial NCT04576091 Trial NCT02154399 Trial NCT01284010 Trial NCT00890032 Trial NCT00811655 Trial NCT00742625 Trial NCT00626483 Trial NCT00470054 Trial NCT00337194 Trial NCT00118235 Trial NCT00110214 Trial NCT00098670 Trial NCT00086827 Patent 8399434

Abstract

The Duke Immune Profiling Core (DIPC) is a Duke Cancer Institute â CCSG designated Shared Resource. The overarching goal of the DIPC is to impact cancer diagnosis and treatment by providing DCI investigators with highest quality human immune profiling data in support of their innovative clinical studies. The DIPC shared resource is comprised of 2 components. The first is a Service component in which DIPC provides comprehensive, highly standardized, state-of-the-art human immunologic profiling services in support of both intra- and extra-mural translational research endeavors, including Phase I/II clinical trials. The second DIPC component focuses on Discovery and utilizes advanced, high-dimensional immunobiologic technologies and resources to stimulate innovative translational research initiatives that will impact existing approaches to cancer diagnosis, prognosis, and treatment. With over 60 years of experience in flow cytometry and immune profiling, we are available to support a wide range of studies from small-scale projects for generating pilot data through clinical trial testing. Additionally, our services include study design, performance of experiments, data collection and analysis, and writing support. Moving forward, we will further enhance our data acquisition and analytical capacity in order to provide DCI members with innovative methods to evaluate patient specimens. The DIPC Shared Resource, which has been in existence since 2019, has provided services to 83 DCI investigators, accounting for 54% of total usage, from all 7 DCI Research Programs during this grant period. During the same period, DIPC provided immune profiling support for 5 cancer immunotherapy clinical trials, and anticipates supporting up to 10 such trials during the next 5-year funding period. Use of this Shared Resource by DCI members contributed to 12 publications over the current project period, 6 of which appeared in high impact journals.

View original record on NIH RePORTER →